These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 29686236)
1. Identifying and exploiting genes that potentiate the evolution of antibiotic resistance. Gifford DR; Furió V; Papkou A; Vogwill T; Oliver A; MacLean RC Nat Ecol Evol; 2018 Jun; 2(6):1033-1039. PubMed ID: 29686236 [TBL] [Abstract][Full Text] [Related]
2. Emergence of Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Fraile-Ribot PA; Del Rosario-Quintana C; López-Causapé C; Gomis-Font MA; Ojeda-Vargas M; Oliver A Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685471 [No Abstract] [Full Text] [Related]
3. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients. Chalhoub H; Tunney M; Elborn JS; Vergison A; Denis O; Plésiat P; Kahl BC; Van Bambeke F; Tulkens PM J Antimicrob Chemother; 2015 May; 70(5):1596-8. PubMed ID: 25587996 [No Abstract] [Full Text] [Related]
4. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15. Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951 [TBL] [Abstract][Full Text] [Related]
5. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients. Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233 [TBL] [Abstract][Full Text] [Related]
6. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria. Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329 [TBL] [Abstract][Full Text] [Related]
7. Mutation-Driven Evolution of Pseudomonas aeruginosa in the Presence of either Ceftazidime or Ceftazidime-Avibactam. Sanz-García F; Hernando-Amado S; Martínez JL Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082283 [TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa. Buyck JM; Luyckx C; Muccioli GG; Krause KM; Nichols WW; Tulkens PM; Van Bambeke F J Antimicrob Chemother; 2017 May; 72(5):1400-1409. PubMed ID: 28137941 [TBL] [Abstract][Full Text] [Related]
9. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam. Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465 [TBL] [Abstract][Full Text] [Related]
10. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16. Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202 [TBL] [Abstract][Full Text] [Related]
11. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa. Ortiz de la Rosa JM; Nordmann P; Poirel L J Antimicrob Chemother; 2019 Jul; 74(7):1934-1939. PubMed ID: 31225611 [TBL] [Abstract][Full Text] [Related]
12. A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing. Bradford PA; Huband MD; Stone GG Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735568 [TBL] [Abstract][Full Text] [Related]
13. Fraile-Ribot PA; Mulet X; Cabot G; Del Barrio-Tofiño E; Juan C; Pérez JL; Oliver A Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674059 [TBL] [Abstract][Full Text] [Related]
14. Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model. Sy SK; Zhuang L; Beaudoin ME; Kircher P; Tabosa MA; Cavalcanti NC; Grunwitz C; Pieper S; Schuck VJ; Nichols WW; Derendorf H J Antimicrob Chemother; 2017 Apr; 72(4):1109-1117. PubMed ID: 28077672 [TBL] [Abstract][Full Text] [Related]
15. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis. Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137 [TBL] [Abstract][Full Text] [Related]
16. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam. Tsivkovski R; Lomovskaya O Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015028 [TBL] [Abstract][Full Text] [Related]
17. Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition. Lahiri SD; Alm RA Antimicrob Agents Chemother; 2016 May; 60(5):3183-6. PubMed ID: 26926646 [TBL] [Abstract][Full Text] [Related]